TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiabetes Mellitus, Type 2InsulinFructosamine

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

Sponsor: Pennington Biomedical Research Center

You may qualify if…

  • Participant reported diagnosis of Type 2 diabetes
  • HbA1c between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL
  • BMI 27-50 kg/m2 (inclusive)
  • Age range - 18 - 65 years (inclusive)
  • On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)
  • Willing to follow all requirements of study protocol including blood draws
  • Under the care of a physician who will be responsible for managing the subject's diabetes
  • Willing to give release to provide their treating MD with information about the trial

You may not qualify if…

  • Not willing or unable to consume study foods including avocados
  • Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months
  • Taking prescription or OTC weight loss medications within last 4 weeks
  • History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
  • History of major surgery within three months of enrollment
  • Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)
  • Renal insufficiency consisting of potassium over 5.5 (mmol/L) on a non-hemolyzed specimen, or a creatinine over 2.5 mg/dL
  • Bilirubin over 3 (mg/dL) or an albumin less than 3 (g/dL)

Where it's recruiting

Louisiana

Baton Rouge

Source: ClinicalTrials.gov · NCT05958368 · last updated 2025-07-31